REG - Oxford Cannabinoid - Notice of General Meeting & Posting of Circular

Oxford Cannabinoid Technologies HoldingsAnnouncement

02/02/2024 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240202:nRSB9160Ba&default-theme=true

RNS Number : 9160B  Oxford Cannabinoid Tech.Holdings  02 February 2024

 

Oxford Cannabinoid Technologies Holdings plc

("OCTP" or the "Company")

 

Notice of General Meeting

&

Posting of Circular

 

Oxford Cannabinoid Technologies Holdings plc (LSE:OCTP), the biotech company
developing prescription cannabinoid medicines, announces that it will today be
posting a circular (the "Circular") together with a form of proxy ("Proxy") to
Shareholders convening a general meeting (the "General Meeting").

The General Meeting is being called to approve a special resolution in respect
of the Company's authority to disapply pre-emption rights in relation to any
conversions under the convertible loan note agreements which the Company
referred to in its announcement of Tuesday 30 January 2024 and which were
entered into and announced earlier today. For further details shareholders
should refer to the announcement released today entitled 'Convertible Loan
Note Agreements'.

Both the Circular and the Proxy will shortly be uploaded to the National
Storage Mechanism and will be  available at:
www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism
(http://www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism)
.

 

These documents are also available on the Company's website at:
https://www.oxcantech.com/investors (https://www.oxcantech.com/investors) and
in hard copy to shareholders upon request to the Company Secretary at Prama
House, 267 Banbury Road, Oxford, England, OX2 7HT.

The Company's General Meeting will be held at the offices of Penningtons
Manches Cooper LLP at 125 Wood Street, London EC2V 7AW on 19 February 2024 at
11.00 a.m.

The Company is aware that the General Meeting gives shareholders the
opportunity to ask the Board questions and encourages shareholders to submit
any such questions in advance via email to the Company Secretary Rob Bennett
at rob@oxcantech.com. Answers to questions received will, where appropriate,
be uploaded onto the Company website following the General Meeting.

The Directors of the Company accept responsibility for the content of this
announcement.

Enquiries:

 

 Oxford Cannabinoid Technologies Holdings plc  +44 (0)20 3034 2820
 Clarissa Sowemimo-Coker (CEO)                 clarissa@oxcantech.com

 Cairn Financial Advisers LLP
 Emily Staples                                 +44 (0)20 7213 0897
 Jo Turner                                     +44 (0) 20 7213 0885

 Axis Capital Markets Limited
 Richard Hutchison                             +44 (0)20 3026 0320

 Acuitas Communications                        020 3745 0293 / 07799 767676
 Simon Nayyar                                  simon.nayyar@acuitascomms.com
 Arthur Dingemans                              arthur.dingemans@acuitascomms.com

 

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company
of Oxford Cannabinoid Technologies Ltd (together the "Group"), a
pharmaceutical Group developing prescription cannabinoid medicines initially
targeting the US$ multi-billion global pain market.

 

OCTP currently has a portfolio of four drug development programmes. Its lead
compound, OCT461201, will initially target neuropathic and visceral pain
(including irritable bowel syndrome ("IBS") and chemotherapy induced
peripheral neuropathy ("CIPN"). The global market for CIPN alone is currently
forecast to reach US$1.17bn by 2028.

 

OCTP's drug development pipeline comprises both natural and synthetic
compounds, and includes compounds targeting trigeminal neuralgia, a severe
type of face pain, and cannabinoid derivatives targeting pain and potentially
other therapeutic areas. Having established an exclusive licence agreement
with Canopy Growth Corporation for their entire pharmaceutical cannabinoid
derivative library, OCTP now has a portfolio of almost five hundred
derivatives and intellectual property rights including fourteen patent
families and associated research data.

 

OCTP has a clearly defined path to commercialisation, revenues and growth. The
Group is developing drug candidates through clinical trials to gain regulatory
approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe
them with confidence. OCTP's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key activities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGBUGDDSBGDGSD